Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Opko Health Inc (OPK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,606,544
  • Shares Outstanding, K 586,332
  • Annual Sales, $ 1,068 M
  • Annual Income, $ -308,870 K
  • 36-Month Beta 2.09
  • Price/Sales 1.49
  • Price/Cash Flow N/A
  • Price/Book 0.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.10
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.63 +4.94%
on 02/08/19
3.87 -28.68%
on 01/25/19
-0.92 (-25.00%)
since 01/22/19
3-Month
2.34 +18.20%
on 12/27/18
3.93 -29.86%
on 01/11/19
-0.79 (-22.25%)
since 11/21/18
52-Week
2.34 +18.20%
on 12/27/18
6.40 -56.88%
on 07/17/18
-0.86 (-23.76%)
since 02/22/18

Most Recent Stories

More News
Research Report Identifies Cognizant Technology Solutions, OPKO Health, MedEquities Realty Trust, AXT, Red Robin Gourmet Burgers, and Dorian LPG with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Cognizant Technology Solutions Corporation...

AXTI : 4.17 (+1.46%)
LPG : 6.00 (-1.64%)
CTSH : 72.10 (+1.07%)
OPK : 2.78 (+1.46%)
RRGB : 31.59 (-6.46%)
MRT : 10.79 (+1.41%)
OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes

OPKO Health, Inc. ("OPKO Health" or the "Company") (NASDAQ: OPK) today announced the pricing of its offering of $200 million aggregate principal amount of Convertible Senior Notes due 2025 (the "Notes")....

OPK : 2.78 (+1.46%)
Johnson Fistel, LLP Announces Investigations of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. and Uxin Limited; Investors Encouraged to Contact Firm

Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies:

MIC : 40.25 (+1.69%)
ABBV : 79.75 (+1.27%)
OPK : 2.78 (+1.46%)
UXIN : 4.59 (+9.29%)
OPKO Health, Inc. Announces Proposed Offering of Convertible Senior Notes

OPKO Health, Inc. ("OPKO Health" or the "Company") (NASDAQ: OPK) today announced that, subject to market and other conditions, it intends to offer $200 million aggregate principal amount of Convertible...

OPK : 2.78 (+1.46%)
OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros(R) 1 Analyzer

OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's point-of-care Sangia Total Prostate Specific Antigen (PSA) Test using the Claros...

OPK : 2.78 (+1.46%)
OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator

OPKO Health, Inc. (NASDAQ: OPK) today announced an update on the ongoing development plans of OPK-88004, a selective androgen receptor modulator (SARM).

OPK : 2.78 (+1.46%)
Future Non-Coverage Determination for 4Kscore Test Posted by Novitas

OPKO Health, Inc. (NASDAQ: OPK) today announced that Novitas Solutions, Inc. has issued a notice of a future non-coverage determination for the 4Kscore test(R) to be effective March 20, 2019. The notice...

OPK : 2.78 (+1.46%)
Today's Research Reports on Trending Tickers: OPKO Health and Endo International

NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb....

OPK : 2.78 (+1.46%)
BioReference Laboratories Supports Federal Employees Amidst Government Shutdown

BioReference Laboratories Inc., an OPKO Health Company (NASDAQ: OPK), today announced that they will offer flexible payment arrangements for federal employees affected by the government shutdown.

OPK : 2.78 (+1.46%)
Here's Why Investors Should Bet on Abiomed (ABMD) Stock Now

Strong contribution from Impella product line is likely to provide Abiomed (ABMD) a competitive edge in the MedTech space.

ABMD : 353.98 (-1.22%)
BDX : 249.30 (+0.65%)
VEEV : 118.97 (+1.81%)
OPK : 2.78 (+1.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade OPK with:

Business Summary

OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.

See More

Key Turning Points

2nd Resistance Point 2.84
1st Resistance Point 2.79
Last Price 2.78
1st Support Level 2.71
2nd Support Level 2.68

See More

52-Week High 6.40
Fibonacci 61.8% 4.85
Fibonacci 50% 4.37
Fibonacci 38.2% 3.89
Last Price 2.78
52-Week Low 2.34

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar